valproic acid has been researched along with Cholangiocellular Carcinoma in 3 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In conclusion, co‑treatment of cholangiocarcinoma cells with TSA or VPA and GEM suppressed EMT with tolerable cytotoxicity." | 5.48 | HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. ( Ji, M; Lee, EJ; Park, SM; Wang, JH, 2018) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 5.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| " We investigated the anticancer effects of VPA in combination with gemcitabine (GEM) in the human cholangiocarcinoma cell line HuCCT1, and explored the mechanisms of the anticancer effects using microarray analysis." | 3.77 | Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis. ( Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T, 2011) |
| "In conclusion, co‑treatment of cholangiocarcinoma cells with TSA or VPA and GEM suppressed EMT with tolerable cytotoxicity." | 1.48 | HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. ( Ji, M; Lee, EJ; Park, SM; Wang, JH, 2018) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 1.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, JH | 1 |
| Lee, EJ | 1 |
| Ji, M | 1 |
| Park, SM | 1 |
| Iwahashi, S | 2 |
| Ishibashi, H | 1 |
| Utsunomiya, T | 2 |
| Morine, Y | 2 |
| Ochir, TL | 1 |
| Hanaoka, J | 2 |
| Mori, H | 2 |
| Ikemoto, T | 2 |
| Imura, S | 2 |
| Shimada, M | 2 |
| Saito, Y | 1 |
3 other studies available for valproic acid and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; E | 2018 |
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell | 2011 |
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cholangioca | 2011 |